

Hemophilia A and B Recombinant Factor Replacement Therapy Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/HE213030CE8FEN.html>

Date: March 2022

Pages: 69

Price: US\$ 3,250.00 (Single User License)

ID: HE213030CE8FEN

Abstracts

Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizures. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.

This report contains market size and forecasts of Hemophilia A and B Recombinant Factor Replacement Therapy in Global, including the following market information:

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hemophilia A and B Recombinant Factor Replacement Therapy market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of %

during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Haemophilia A Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hemophilia A and B Recombinant Factor Replacement Therapy include Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Unique. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemophilia A and B Recombinant Factor Replacement Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Type, 2021 (%)

Haemophilia A

Haemophilia B

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Ambulatory Surgical Centers

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hemophilia A and B Recombinant Factor Replacement Therapy revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hemophilia A and B Recombinant Factor Replacement Therapy
revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Novo Nordisk

Baxalta

Bayer

Biogen

CSL Behring

Emergent Biosolutions

Spark therapeutics

Uniquire

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HEMOPHILIA A AND B RECOMBINANT FACTOR REPLACEMENT THERAPY OVERALL MARKET SIZE

- 2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size: 2021 VS 2028
- 2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market
- 3.2 Top Global Hemophilia A and B Recombinant Factor Replacement Therapy Companies Ranked by Revenue
- 3.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Companies
- 3.4 Top 3 and Top 5 Hemophilia A and B Recombinant Factor Replacement Therapy Companies in Global Market, by Revenue in 2021

3.5 Global Companies Hemophilia A and B Recombinant Factor Replacement Therapy Product Type

3.6 Tier 1, Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market

3.6.1 List of Global Tier 1 Hemophilia A and B Recombinant Factor Replacement Therapy Companies

3.6.2 List of Global Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Markets, 2021 & 2028

4.1.2 Haemophilia A

4.1.3 Haemophilia B

4.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts

4.2.1 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022

4.2.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028

4.2.3 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Ambulatory Surgical Centers

5.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts

5.2.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022

5.2.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028

5.2.3 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2021 & 2028

6.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts

6.2.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022

6.2.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028

6.2.3 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028

6.3.2 US Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.3.3 Canada Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.3.4 Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028

6.4.2 Germany Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.3 France Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.4 U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.5 Italy Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.6 Russia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.7 Nordic Countries Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.4.8 Benelux Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028

6.5.2 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.5.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.5.4 South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.5.5 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.5.6 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028

6.6.2 Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.6.3 Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028

6.7.2 Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.7.3 Israel Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.7.4 Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

6.7.5 UAE Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.1.4 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.1.5 Pfizer Key News

7.2 Novo Nordisk

7.2.1 Novo Nordisk Corporate Summary

7.2.2 Novo Nordisk Business Overview

7.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.2.4 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.2.5 Novo Nordisk Key News

7.3 Baxalta

7.3.1 Baxalta Corporate Summary

7.3.2 Baxalta Business Overview

7.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.3.4 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.3.5 Baxalta Key News

7.4 Bayer

7.4.1 Bayer Corporate Summary

7.4.2 Bayer Business Overview

7.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.4.4 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.4.5 Bayer Key News

7.5 Biogen

7.5.1 Biogen Corporate Summary

7.5.2 Biogen Business Overview

7.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.5.4 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.5.5 Biogen Key News

7.6 CSL Behring

7.6.1 CSL Behring Corporate Summary

7.6.2 CSL Behring Business Overview

7.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.6.4 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.6.5 CSL Behring Key News

7.7 Emergent Biosolutions

7.7.1 Emergent Biosolutions Corporate Summary

7.7.2 Emergent Biosolutions Business Overview

7.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.7.4 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.7.5 Emergent Biosolutions Key News

7.8 Spark therapeutics

7.8.1 Spark therapeutics Corporate Summary

7.8.2 Spark therapeutics Business Overview

7.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.8.4 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.8.5 Spark therapeutics Key News

7.9 Uniqure

7.9.1 Uniqure Corporate Summary

7.9.2 Uniqure Business Overview

7.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings

7.9.4 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)

7.9.5 Uniqure Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hemophilia A and B Recombinant Factor Replacement Therapy Market Opportunities & Trends in Global Market

Table 2. Hemophilia A and B Recombinant Factor Replacement Therapy Market Drivers in Global Market

Table 3. Hemophilia A and B Recombinant Factor Replacement Therapy Market Restraints in Global Market

Table 4. Key Players of Hemophilia A and B Recombinant Factor Replacement Therapy in Global Market

Table 5. Top Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hemophilia A and B Recombinant Factor Replacement Therapy Product Type

Table 9. List of Global Tier 1 Hemophilia A and B Recombinant Factor Replacement Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hemophilia A and B Recombinant Factor Replacement

Therapy Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 32. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 33. Novo Nordisk Corporate Summary

Table 34. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 35. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 36. Baxalta Corporate Summary

Table 37. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 38. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 39. Bayer Corporate Summary

Table 40. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 41. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 42. Biogen Corporate Summary

Table 43. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 44. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 45. CSL Behring Corporate Summary

Table 46. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 47. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 48. Emergent Biosolutions Corporate Summary

Table 49. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 50. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 51. Spark therapeutics Corporate Summary

Table 52. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 53. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

Table 54. Uniqure Corporate Summary

Table 55. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings

Table 56. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Hemophilia A and B Recombinant Factor Replacement Therapy Segment by Type in 2021

Figure 2. Hemophilia A and B Recombinant Factor Replacement Therapy Segment by Application in 2021

Figure 3. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2021

Figure 8. By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 9. By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 10. By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 11. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 12. US Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 16. Germany Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 17. France Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 24. China Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 30. Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028

Figure 33. Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement

Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Uniquire Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Hemophilia A and B Recombinant Factor Replacement Therapy Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/HE213030CE8FEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE213030CE8FEN.html>